Mitotech Ltd, a UK-based clinical-stage biotechnology company developing novel pharmaceuticals targeting mitochondria, today announced that its CEO, Natalia Perekhvatova, is invited to present during Retina Livestream organized by Eyecelerator – a partnership between AAO and ASCRS. The Livestream will take place on September 30, 2020 at 9:00 a.m. PST:
https://www.eyecelerator.com/live-stream-october-2020
"This event is a great opportunity for Mitotech to highlight its back-of-the-eye clinical program in indications like Dry AMD and LHON, we are looking forward to it," said Natalia Perekhvatova.
About Mitotech Ltd
Mitotech Ltd is a UK-based biotechnology company developing novel drugs for treatment of predominantly age-related disorders. The core technology behind Mitotech products is based on a novel class of small molecules – mitochondria targeting cardiolipin peroxidation inhibitors. Company's lead compound SkQ1 is being developed in several drug formulations covering a variety of therapeutic areas with major focus on ophthalmology and neurodegenerative diseases. In VISTA-1 – a Phase 2b/3 clinical study in the United States (NCT03764735) - SkQ1 showed evidence of efficacy in reducing both the signs and symptoms in Dry Eye subjects. A Phase 3 pivotal study (VISTA-2) is currently underway with topline data expected by the end of 2020. Dry AMD and LHON programs for SkQ1 ophthalmic solution are at pre-Phase 2 stage with Phase 2 studies projected to start in 2021.